NCI at AACR Virtual Annual Meeting 2020
The National Cancer Institute (NCI) is participating in the American Association for Cancer Research (AACR) Virtual Annual Meetings to be held April 27-28 and June 22-24, 2020.
Virtual Annual Meeting I: April 27-28
Thank you for joining us for the first AACR Annual Virtual Meeting. You can access all presentations—including those featuring NCI speakers—from AACR Annual Virtual Meeting I on-demand. Creating an account is required, but is free and open to the public.
NCI Leadership Presentation
NCI Deputy Director Speaks about Impact of COVID-19 on Cancer Research
Dr. Singer presented about the impact that the COVID-19 pandemic has had on NCI and the extramural community. She gave an overview of NCI’s efforts to contribute to the COVID-19 crisis by pivoting some cancer research activities to focus on SARS-CoV-2 as well as highlighting examples of how NCI continues to make progress in cancer research. Dr. Singer also provided some details on how NCI, working with NIH, has implemented new flexibilities for the cancer research community during this crisis.
Some of these flexibilities include:
- Extended deadlines for applications
- Use of NCI grant funds for salaries and stipends
- Flexibility on extensions of projects and reporting requirements
- Extensions for early stage investigators and trainees
A comprehensive list of COVID-related resources from NCI is available at Coronavirus: Guidance for Cancer Researchers.
Due to the timeliness of the presentation provided by Dr. Singer, NCI is also providing direct access to the slides and video below:
Presentations and Poster Sessions Featuring NCI Staff
|Presentation Title and Time||NCI Participant(s)|
Advancing Cancer Research through an International Registry; AACR Project GENIE Use Cases
Learn about the Variant Interpretation for Cancer Consortium efforts on harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. This presentation will also examine how the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) was utilized for evaluating meta-knowledgebase value.
Translational Prevention Studies
This minisymposium presents a multidisciplinary program of state-of-the-art laboratory, clinical, and translational research addressing multiple aspects of prevention research. Abstracts describing epidemiologic studies, animal model development, biomarker identification, and chemoprevention studies will be presented.
Adoptive Cell Transfer Therapy
Learn how this trial tested novel, humanized bispecific CD19/CD22 CAR T cells, developed to overcome resistance with approved CAR T-cell therapies, in patients with relapsed/refractory acute B-cell lymphoblastic leukemia. Eight of 11 patients who received the treatment had objective responses, with four minimal residual disease (MRD)-negative complete responses and four partial responses. The treatment was well tolerated, with best responses in patients who did not receive prior CAR T-cell therapy.
Nirali N. Shah
|Immunotherapy Clinical Trials 2
A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study
This presentation discusses a randomized trial of atezolizumab versus atezolizumab and cobimetinib in patients with cholangiocarcinoma. This trial is based on preclinical data suggesting that MEK inhibition may potentiate the efficacy of immunotherapy. The trial demonstrated a modest but statistically significant increase in the progression free survival on the combination arm. Correlative studies are underway and may provide guidance for development of this or other combination regimens for patients afflicted by this horrible disease.
|Novel Targets and Therapies
This session showcases the identification of new drug targets using small molecules and the exploration of novel cell surface receptor using a proprietary chemotherapy delivery platform.
|Naoko Takebe (session co-chair)|
|Predictive Biomarkers for Immunotherapeutics
As more gene panel-based assays are developed to estimate tumor mutation burden (TMB), harmonization is emerging as an unmet need and is a key goal of the Friends of Cancer Research TMB Harmonization Project. The investigators report on Phase 2B of their study, which aims to characterize variability in TMB measurements in clinical samples and to establish best practices for estimating and aligning TMB in order to improve consistency across panels.
|Laura M. Yee
Evaluating Cancer Genomics from Normal Tissues through
Utilizing targeted, deep coverage next-generation sequencing data (MSK-IMPACT) to identify clonal hematopoiesis-related mutations, we show that patients previously treated with oncologic therapy have increased rates of clonal hematopoiesis, with increased mutation frequency in DNA damage response-related genes. Improved understanding of clonal hematopoiesis-related mutational features could impact clinical practice for early detection and treatment decisions in patients at high risk of progressing to therapy-related myeloid neoplasia.
Learn about the development of the SOP for the interpretation of oncogenicity of somatic mutations. The discussion will include the rationale, intended scope and key features of the SOP.
Preclinical and clinical data have suggested that downstream inhibition with a MEK inhibitor, such as binimetinib, might be efficacious for NRAS-mutated cancers. In the NCI-MATCH Precision Medicine study, Z1A patients with refractory solid tumors harboring codon 12, 13, or 61 NRAS-mutations were enrolled on a single arm study of binimetinib 45 mg twice daily. While the trial did not meet the primary endpoint (RR=2.1%), it was noted that patients whose tumors harbored the codon 61 mutation had a significantly longer OS (p=0.04) and PFS (p=0.006) than those with tumors harboring codon 12 or 13 NRAS-mutations. Further study of binimetinib in tumors with codon 61 mutations may be warranted.
Helen X Chen
|Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa||Shizuko Sei
Robert H. Shoemaker
|Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors||Naoko Takebe|
|Characterization of PEN-866, a Heat Shock Protein 90 (HSP90) binding conjugate of SN-38, in patient plasma and tumors from the first in human study||Anish Thomas
|A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)||Elad Sharon|
Virtual Annual Meeting II: June 22-24
Additional details will be provided for this meeting once available. Be sure to check back regularly for these NCI updates at the Virtual Annual Meeting II.